St-Jean, Audray
Chateau, Dan
Dahl, Matthew
Ernst, Pierre
Daneman, Nick
Sketris, Ingrid S.
Zhang, Jianguo
Marra, Fawziah
Quail, Jacqueline
Bugden, Shawn
,
Funding for this research was provided by:
Canadian Institutes of Health Research
Article History
Received: 6 May 2021
Accepted: 21 July 2021
First Online: 3 August 2021
Declarations
:
: Ethical approval was obtained at each participating site including: the Conjoint Health Research Ethics Board at the University of Calgary, the Clinical Research Ethics Board at the University of British Columbia, the Health Research Ethics Board at the University of Manitoba, and the Health Sciences Research Ethics Board at Dalhousie University. Given the use of routinely collecting data, this study was exempt for ethics review in Ontario, as authorized under Sect. 45 of Ontario’s <i>Personal Health Information Protection Act</i>. This study was exempt from ethics review by the Research Services and Ethics Office at the University of Saskatchewan. This study used anonymized administrative data, and the requirement of informed consent was therefore waived at each participating site. Specifically, informed consent to participate was waived by the following ethics boards: the Conjoint Health Research Ethics Board at the University of Calgary, the Clinical Research Ethics Board at the University of British Columbia, the Health Research Ethics Board at the University of Manitoba, and the Health Sciences Research Ethics Board at Dalhousie University.
: Not applicable.
: Dr. Marra received research funds from Pfizer from 2016 to 2018 for studies not involving fluoroquinolones. The remaining authors have no relevant conflicts of interest to disclose.